Plain-English translation of NCT07605572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how semaglutide, a medication commonly prescribed for weight loss and diabetes management, may affect dry eye disease. About half of the study participants will receive this medication for their weight or diabetes, while the other half will not receive it. The study will compare how dry eye symptoms change between the two groups.
Doctors have noticed that people taking this type of medication sometimes report changes in their eye health, but no one has formally studied this connection yet. This research will help clarify whether the medication actually affects dry eyes and how, so doctors can better support patients taking it.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be placed into one of two groups: one group will receive semaglutide therapy for weight loss or diabetes management, and the other group will not receive the medication but will be matched with participants in the treatment group based on age, sex, and body weight. Both groups will likely have their eye health monitored and assessed over time to see if the medication affects dry eye symptoms.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Greece
Enrollment target
~100 participants
Started
March 2026
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vaia Lambadiari, MD, PhD
Attikon Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.